Sol Gel Technologies Ltd
NASDAQ:SLGL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sol Gel Technologies Ltd
Capital Expenditures
Sol Gel Technologies Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Capital Expenditures
-$47k
|
CAGR 3-Years
35%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Capital Expenditures
-$501m
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
PolyPid Ltd
NASDAQ:PYPD
|
Capital Expenditures
-$210k
|
CAGR 3-Years
35%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Capital Expenditures
-$5.5m
|
CAGR 3-Years
-114%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-30%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Capital Expenditures
-₪1m
|
CAGR 3-Years
7%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Capital Expenditures
-₪6.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
22%
|
CAGR 10-Years
8%
|
|
Sol Gel Technologies Ltd
Glance View
Sol-Gel Technologies Ltd. is a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
See Also
What is Sol Gel Technologies Ltd's Capital Expenditures?
Capital Expenditures
-47k
USD
Based on the financial report for Dec 31, 2025, Sol Gel Technologies Ltd's Capital Expenditures amounts to -47k USD.
What is Sol Gel Technologies Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
36%
Over the last year, the Capital Expenditures growth was -2 250%. The average annual Capital Expenditures growth rates for Sol Gel Technologies Ltd have been 35% over the past three years , 36% over the past five years .
